



ensuring knowledge, enhancing quality

A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts

<www.jpag.org>

Assuring the quality of medicines III; aseptic products

Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA
Thursday 9th May 2019

The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.

This symposium is particularly useful as continuing professional development for qualified persons, others involved in the manufacture and quality control of aseptic products in industry and the NHS, as well as those involved in process development.

There will be an opportunity to present posters on the broad subject area of the symposium, subject to acceptance of a submitted abstract.

There will be adequate time after each presentation to discuss case studies and practical implications.

Interested in this meeting?

Please visit the JPAG website for full details at www.jpag.org

Sponsors of the Joint Pharmaceutical Analysis Group



Programme

10:00 Introduction

10:05 Annex 1 update and current inspection findings in aseptic manufacturers' facilities
Alan Moon, Senior MHRA Inspector and Annex 1 representative

10:45 Best practice in environmental monitoring
Tim Sandle, Committee member, Pharmaceutical Microbiology Interest Group (Pharmig)

11:25 Refreshments

11:40 Development of PHSS Clarity on GMP Guidance Notes to assist assured quality of sterile medicinal products
James Drinkwater, Chairman PHSS

12:20 Panel discussion; questions submitted by delegates and from audience

12:40 Lunch, posters and exhibition

13:40 GSK Corporate Audit findings and how these are risk assessed
Di Morris, GlaxoSmithKline

14:20 Implementing and managing PUPSIT with practical examples of overcoming common challenges
Dr Paul Beckett, Merck Millipore

15:00 Refreshments

15:20 Sterility assurance for cell based therapies
Dr Dawn Hiles, Newcastle Cellular Therapies

16:00 How to write a contamination control strategy
Speaker GSK, TBA

16:40 Final round-up

16:45 Close

Delegate information

Registration fees

Full fee £295

Fee for members of JPAG ** £195

Fee for bona fide student in full-time study £45

Fee for retired or unemployed members of JPAG £45

** Details on how members of RPS and RSC can join JPAG are found on the JPAG website.

Registration and payment of registration fees

You can register on-line at www.jpag.org. Please SIGN IN to the site on your first visit before registering for an event; this will ensure that post-event delegate material is fully available to you personally.

Full payment is required at the time of registration. Please pay ON-LINE by credit card (via Paypal). Notification that a registration has been accepted will be confirmed by e-mail to your registered e-mail address. If you have not received notification within five working days please contact JPAG at info@jpgag.org. An invoice confirming your registration can be downloaded from the JPAG website. NO OTHER INVOICE WILL BE SUPPLIED. If payment has not been received prior to the event, then entry to the event will be at the discretion of JPAG. Payments may also be made by bank transfer.

Cancellation policy

Meeting registrations once made and accepted by JPAG are liable for payment and are not refundable. However, notified substitutions are permitted at any time prior to the meeting (see below).

JPAG reserves the right to cancel a meeting due to circumstances beyond its control. In this case, JPAG will notify attendees by a message to their registered e-mail address at the earliest reasonable opportunity. It is the responsibility of registered delegates to monitor their e-mail and ensure their registered e-mail address is correct. In the event of cancellation, a full refund of payments will be provided. However JPAG will not be liable, to the extent permitted by law, for any consequential loss or damage arising from the meeting cancellation.

Substitutions

Substitute attendees from the same organisation are accepted at any time with no administration charge. Please notify JPAG in writing via e-mail to events@jpgag.org with details of substitute attendees. Substitute attendees must possess an account or register a new account on the JPAG website in order for their registration to be processed.

No refund is payable in relation to any substitution. The full meeting rate will be applied if the substitute attendee is not eligible for a discount and any additional payment is required before a registration can be accepted.

Alterations to the programme

JPAG reserves the right to alter the meeting programme, speakers, date or venue in the event of circumstances beyond its control. For the complete Terms and Conditions, please see the JPAG website.

Other information

Information on the programme, submission of abstracts for Poster presentation, location of the venue and local hotels, and JPAG membership is available on the JPAG website at: www.jpag.org. Other enquiries should be sent to events@jpgag.org

The contact details you provide on SIGN IN may be used to inform you about future JPAG, RPS and RSC events, products and services by post, phone or e-mail. However, you can elect not to receive information at any time by updating your profile on the website.

JPAG symposium programme

Thursday 21st March 2019

Stability IV: Developments in stability testing and evaluation

Royal Society of Chemistry, London

Continuing our successful series of stability meetings, this is an essential event for anyone concerned with the management and assessment of drug stability:

- Hear from individuals involved in the regulation and inspection of stability and GDP
- Learn from industry experts on scientific developments in stability study design and interpretation
- Debate practical issues for evaluating data and predicting stability
- Examine ways to improve compliance and productivity in stability testing
- Network with other professionals and exhibitors

Speakers:

Dr Jonathan Bright - AstraZeneca

John Cleverley - Clarivate Analytics

Dr Paul Fullerton - AMRI

Conor Jamieson - Sandwell and West Birmingham NHS Trust

Dr Rachel Orr - GlaxoSmithKline

Dr Garry Scrivens - Pfizer

Susan Smith - AstraZeneca

Dr Maria Krisch - Freethink Technologies Inc

Download the Brochure and register now at www.jpag.org/cp109

Thursday 9th May 2019

Assuring the quality of medicines III; aseptic products

Royal Society of Chemistry, London

The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.

There will be adequate time after each presentation to discuss case studies and practical implications.

Speakers:

Dr Paul Beckett - Merck Millipore

James Drinkwater - Pharmaceutical and Healthcare Sciences Society

Dawn Hiles - Newcastle Cellular Therapies Facility, International Centre for Life

Alan Moon - MHRA

Di Morris - GlaxoSmithKline

Dr Tim Sandle - Committee member, Pharmaceutical Microbiology Interest Group (Pharmig)

Register now at www.jpag.org/cp113

Thursday 11th July 2019

Analytical challenges of new modalities

Royal Society of Chemistry, London

The purpose of this symposium is to Identify areas for harmonisation of oligonucleotide development and propose solutions to influence the external regulatory environment; expediting patient access to revolutionary medicines

Register now at www.jpag.org/cp110

Interested in any of these meetings?

Please visit the JPAG website for full details at www.jpag.org

Sponsors of the Joint Pharmaceutical Analysis Group

